Items Tagged ‘midostaurin’

November 17, 2016

FDA Priority Review Granted for Midostaurin in Leukemia


The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by […]

View full entry

Tags: Acute Myeloid Leukemia, AML, fda, FLT3 mutation, itchy skin, Leukemia, mast cell, mastocytosis, midostaurin, News, PKC412

December 15, 2015

Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia


The targeted agent, midostaurin, has demonstrated a survival improvement among patients with acute myeloid leukemia (AML) that has the TMS-like tyrosine kinase 3 (FLT3) mutation. These results were presented at a plenary session at the 2015 annual meeting of the American Society of Hematology (ASH), in Orlando, Florida. Acute myeloid leukemia is a type of […]

View full entry

Tags: Acute Myeloid Leukemia, FLT3, Leukemia, midostaurin, myeloid leukemia, News, targeted agent